The ALS-FTD spectrum represents a continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and pathological features. This page provides a unified mechanistic model that integrates the three major pathogenic pathways driving both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD): TDP-43 proteinopathy, C9orf72 hexanucleotide repeat expansion, and dipeptide repeat protein (DPR) toxicity. Understanding how these mechanisms converge on shared downstream pathways provides critical insights for developing therapeutics that can address both conditions simultaneously. [1]
ALS and FTD exist on a clinical spectrum where approximately 50% of ALS patients demonstrate cognitive or behavioral impairment, and approximately 15% of FTD patients develop motor neuron signs 1. The revised Strong criteria (2017) formalized this spectrum with classifications ranging from cognitively normal ALS (ALS-cn) to full ALS-FTD overlap 2. [2]
At least nine genes cause both ALS and FTD, with mutations in C9orf72, TARDBP, and FUS representing the most common shared genetic causes 3. This genetic convergence points to shared pathogenic mechanisms that can be targeted therapeutically. [3]
TDP-43 is a 414-amino acid RNA-binding protein encoded by the TARDBP gene, primarily localized to the nucleus where it performs essential functions 4:
The hallmark of TDP-43 proteinopathy is the mislocalization of TDP-43 from the nucleus to cytoplasmic aggregates, observed in approximately 97% of ALS cases and 50% of FTD cases 5:
The C9orf72 expansion causes TDP-43 pathology through multiple mechanisms:
The C9orf72 gene contains a GGGGCC (G4C2) hexanucleotide repeat in its first intron 6:
| Repeat Count | Classification | Clinical Significance |
|---|---|---|
| 2-30 | Normal | No disease risk |
| 30-50 | Intermediate | Uncertain risk |
| 50-200 | Pathological | Full penetrance |
| 200-1000+ | Highly Pathological | Earlier onset |
The C9orf72 expansion causes disease through three interconnected mechanisms:
Repeat-associated non-AUG (RAN) translation produces five dipeptide repeat proteins from both sense and antisense transcripts 7:
| DPR | Reading Frame | Sense/Antisense | Key Properties |
|---|---|---|---|
| Poly-GA | +1 | Sense | Most abundant, forms inclusions |
| Poly-GP | +2 | Sense | Less aggregation-prone |
| Poly-GR | +3 | Sense | Arginine-rich, most toxic |
| Poly-PA | +1 | Antisense | Aggregates in nuclei |
| Poly-PR | +2 | Antisense | Arginine-rich, highly toxic |
The different DPR species cause neuronal dysfunction through distinct mechanisms:
Loss of nuclear TDP-43 function leads to:
Multiple mechanisms converge on proteostatic stress:
Arginine-rich DPRs (poly-GR, poly-PR) directly disrupt nuclear pore function 9:
TDP-43 and DPRs both affect stress granule dynamics:
The selective vulnerability of motor neurons and frontal/temporal neurons in ALS-FTD reflects:
| Cell Type | Primary Pathology | Clinical Manifestation |
|---|---|---|
| Motor neurons | TDP-43 inclusions | ALS (weakness, atrophy) |
| Frontal cortex neurons | TDP-43 inclusions | FTD (behavioral/cognitive) |
| Upper motor neurons | TDP-43 + DPRs | Spasticity |
| Lower motor neurons | TDP-43 + DPRs | Weakness, fasciculations |
The unified mechanistic model suggests therapeutic strategies that could benefit both ALS and FTD:
| Mechanism | Therapeutic Approach | Status |
|---|---|---|
| TDP-43 aggregation | ASOs targeting TDP-43 mRNA | Preclinical |
| C9orf72 expansion | ASOs reducing repeat RNA | Clinical trials |
| DPR toxicity | Small molecules blocking RAN translation | Preclinical |
| Proteostasis | Autophagy enhancers | Clinical trials |
| Nuclear transport | Nuclear pore stabilizers | Preclinical |
Shared mechanisms enable cross-disease biomarkers:
Additional evidence sources: [4] [5] [6] [7] [8] [9]
Ringholz et al. Prevalence of frontotemporal dementia in ALS (2005). 2005. ↩︎
Strong et al. Amyotrophic lateral sclerosis frontotemporal spectrum disorder (2017). 2017. ↩︎
Rohrer et al. C9orf72 expansions cause ALS-FTD (2011). 2011. ↩︎
Lagier-Tourenne & Cleveland, TDP-43 and FUS in ALS (2010). 2010. ↩︎
Neumann et al. TDP-43 in ALS and FTLD (2006). 2006. ↩︎
DeJesus-Hernandez et al. C9orf72 repeat expansion (2011). 2011. ↩︎
Mori et al. Dipeptide repeat proteins in C9orf72 ALS/FTD (2013). 2013. ↩︎
Ling et al. Cryptic exon splicing in TDP-43 loss (2015). 2015. ↩︎
Zhang et al. Nucleocytoplasmic transport disruption by DPRs (2015). 2015. ↩︎